Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01195792 | A 35 Day Study to Investigate the Effects of GSK1521498 on Bodyweight in Obese Subjects With Over-Eating Behaviours. | PHASE2 | COMPLETED | 60 | — | — | Sep 1, 2010 | May 1, 2011 | Dec 1, 2016 | 3 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| 2 mg GSK1521498 | EXPERIMENTAL | Approximately 20 subjects will be randomised to receive 2 mg GSK1521498. The drug is being developed for the treatment of obesity due to excessive consumption of high calorie foods |
| 5 mg GSK1521498 | EXPERIMENTAL | Approximately 20 subjects will be randomised to receive 5 mg GSK1521498. The drug is being developed for the treatment of obesity due to excessive consumption of high calorie foods |
| Placebo | PLACEBO_COMPARATOR | Approximately 20 subjects will be randomised to receive matching placebo. |
| Name | Type | Description |
|---|---|---|
| GSK1521498 | DRUG | GSK1521498 2mg or 5mg will be given for up to 35 days and subjects will be assessed weekly |
| Placebo | DRUG | Placebo will be given for up to 35 days and subjects will be assessed weekly |
Inclusion Criteria: * Obese but essentially healthy male or female between 18 and 60 years of age inclusive. * Body Mass Index greater than or equal to 30 kg/m2. * Binge Eating Scale (BES) score that is greater than or equal to 19 at screening assessment. * A female subject of child-bearing potenti...